How is coronavirus affecting our operations? Learn more

New Therapies Targeting Parkinson’s Disease May Cause Harm

In a post dated 20 March, Science Daily  reports that NorthShore University HealthSystem (NorthShore) and Mayo Clinic researchers have partnered on a study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein — a gene whose function is involved in the development and progression of Parkinson’s disease — may accelerate disease progression and increase the risk of physical incapacitation and dementia. If replicated, the findings will have profound implications for therapies under development for Parkinson’s disease.

Print this page